Royalty Pharma CFO acquires 6,168 shares via Rule 16b-3 award

Royalty Pharma (RPRX) EVP & CFO reported an exempt acquisition of 6,168 Class A Ordinary Shares on 11/05/2025 at $0 per share under Rule 16b-3, tied to the settlement of Equity Performance Awards.

Rhea-AI Filing Summary

Royalty Pharma (RPRX) EVP & CFO reported an exempt acquisition of 6,168 Class A Ordinary Shares on 11/05/2025 at $0 per share under Rule 16b-3, tied to the settlement of Equity Performance Awards.

Following this transaction, 58,510 shares were beneficially owned through TPC RP EPA1 LLC. The filing also lists additional holdings in various accounts, including 1,500 shares held directly and 790,000 shares held indirectly by TPC RP 2021, LLC.

Insider Trade Summary

Grant/Award: 6,168 shares

Grant/Award 6 txns

Insider Coyne Terrance P.

Role EVP & CFO

Type	Security	Shares	Price	Value
Grant/Award	Class A Ordinary Shares	6,168	$0.00	$0.00
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--

Holdings After Transaction: Class A Ordinary Shares — 58,510 shares (Indirect, TPC RP EPA1 LLC); Class A Ordinary Shares — 1,500 shares (Direct); Class A Ordinary Shares — 790,000 shares (Indirect, By TPC RP 2021, LLC); Class A Ordinary Shares — 24,170 shares (Indirect, By Spouse's IRA); Class A Ordinary Shares — 23,270 shares (Indirect, By IRA); Class A Ordinary Shares — 1,450 shares (Indirect, By Spouse)

Footnotes (1)

1. F1. Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Royalty Pharma (RPRX) disclose in this Form 4?

The EVP & CFO reported an exempt acquisition of 6,168 Class A Ordinary Shares under Rule 16b-3 related to Equity Performance Awards.

How many shares were acquired and at what price?

The filing reports 6,168 shares acquired at $0 per share.

When did the transaction occur?

The reported transaction date is 11/05/2025.

What is the basis for the exempt acquisition?

It reflects acquisition under Rule 16b-3 in connection with the settlement of Equity Performance Awards.

How many shares were beneficially owned after the transaction through TPC RP EPA1 LLC?

The filing shows 58,510 shares beneficially owned through TPC RP EPA1 LLC following the transaction.

What other holdings are listed in the filing?

Additional holdings include 1,500 shares held directly and 790,000 shares held indirectly by TPC RP 2021, LLC, among others.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/07/2025 - 04:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coyne Terrance P.

(Last) (First) (Middle)

C/O ROYALTY PHARMA PLC

110 EAST 59TH STREET

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & CFO

3. Date of Earliest Transaction (Month/Day/Year)
11/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	11/05/2025		A		6,168(1)	A	$0	58,510	I	TPC RP EPA1 LLC
Class A Ordinary Shares								1,500	D
Class A Ordinary Shares								790,000	I	By TPC RP 2021, LLC
Class A Ordinary Shares								24,170	I	By Spouse's IRA
Class A Ordinary Shares								23,270	I	By IRA
Class A Ordinary Shares								1,450	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

Remarks:

	/s/ Sean Weisberg, as Attorney-in-Fact for Terrance P. Coyne	11/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.